NIH-Funding

Methodology and Measurement in the Behavioral and Social Sciences (R01) Clinical Trials Optional

NIH Funding Announcements - Tue, 11/21/2017 - 03:03
Funding Opportunity PAR-18-352 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified researchers to submit grant applications aimed at improving and developing methodology in the behavioral and social sciences through innovations in research design, measurement, data collection and data analysis techniques.
Categories: NIH-Funding

Methodology and Measurement in the Behavioral and Social Sciences (R21) Clinical Trials Optional

NIH Funding Announcements - Tue, 11/21/2017 - 03:03
Funding Opportunity PAR-18-378 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified researchers to submit grant applications aimed at improving and developing methodology in the behavioral and social sciences through innovations in research design, measurement, data collection and data analysis techniques.
Categories: NIH-Funding

Population Health Interventions: Integrating Individual and Group Level Evidence (R01) Clinical Trials Not Allowed

NIH Funding Announcements - Tue, 11/21/2017 - 02:43
Funding Opportunity PA-18-356 from the NIH Guide for Grants and Contracts. To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.
Categories: NIH-Funding

Population Health Interventions: Integrating Individual and Group Level Evidence (R21)- Clinical Trials Not Allowed

NIH Funding Announcements - Tue, 11/21/2017 - 02:43
Funding Opportunity PA-18-406 from the NIH Guide for Grants and Contracts. To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.
Categories: NIH-Funding

Mentored Patient-Oriented Research Career Development Award (Parent K23 - Clinical Trial Required)

NIH Funding Announcements - Tue, 11/21/2017 - 02:05
Funding Opportunity PA-18-374 from the NIH Guide for Grants and Contracts. The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.
Categories: NIH-Funding

Mentored Patient-Oriented Research Career Development Award (Parent K23 - Independent Clinical Trials Not Allowed)

NIH Funding Announcements - Tue, 11/21/2017 - 02:05
Funding Opportunity PA-18-375 from the NIH Guide for Grants and Contracts. The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.
Categories: NIH-Funding

By: SBIR PI

WriteEdit-Grant Questions Blog - Mon, 11/20/2017 - 20:33

Thanks very much!

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Mon, 11/20/2017 - 13:16

This is my mistake – I am so sorry. I forgot that the Cycle II SBIR/STTR applications have a separate review cycle and are completed in the same FY as they are submitted. Technically, you could set your start date as July 5 for Cycle II.

My advice about 1 vs 2 applications still holds though (you won’t get dinged, but only submit 2 if both are strong); NCAB meets in early Sept, so the timing could still be about the same (for Cycle II & III submissions), too.

Aside from the review process and timing, your PO would give the best insight about IC priorities and willingness to fund 2 simultaneously (if both score competitively).

Categories: NIH-Funding

By: MWEG Active at NIH Paylines & Resources (& update to How the NIH Can Help You Get Funded) | Medical Writing, Editing & Grantsmanship

WriteEdit-Grant Questions Blog - Mon, 11/20/2017 - 13:01

[…] to the main blog in years, I continue to actively answer questions and encourage discussion at NIH Paylines & Resources (where I also update NIH paylines as they are posted), Discussion: NIH Scores-Paylines-Policy-Peer […]

Categories: NIH-Funding

NCI Transition Career Development Award to Promote Diversity (K22 - No Clinical Trials)

NIH Funding Announcements - Mon, 11/20/2017 - 12:43
Funding Opportunity PAR-18-366 from the NIH Guide for Grants and Contracts. The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.
Categories: NIH-Funding

NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)

NIH Funding Announcements - Mon, 11/20/2017 - 12:43
Funding Opportunity PAR-18-367 from the NIH Guide for Grants and Contracts. The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), within the Center to Reduce Cancer Health Disparities (CRCHD) (http://crchd.cancer.gov/) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds nationally underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position.
Categories: NIH-Funding

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 11/20/2017 - 12:21
Funding Opportunity RFA-CA-18-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Categories: NIH-Funding

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 11/20/2017 - 12:21
Funding Opportunity RFA-CA-18-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are non-responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Categories: NIH-Funding

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 11/20/2017 - 12:21
Funding Opportunity RFA-CA-18-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Categories: NIH-Funding

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 11/20/2017 - 12:21
Funding Opportunity RFA-CA-18-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Categories: NIH-Funding

By: SBIR PI

WriteEdit-Grant Questions Blog - Mon, 11/20/2017 - 08:47

Thank you for the clarification. Would you please further clarify why the January 5 2018 SBIR submission would be considered FY19? Typically, we set our start dates 8 months from the submission date – so for a January 2018 SBIR submission to NIH, I would put the start date as September 5 2018.

Categories: NIH-Funding

Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)

NIH Funding Announcements - Mon, 11/20/2017 - 02:52
Funding Opportunity RFA-OD-18-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support New Investigators in the biomedical, behavioral, and social sciences who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applicants are encouraged to conduct projects that ultimately have potential to inform regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using designated funds from the FDA CTP for tobacco regulatory science. Research findings generated from this FOA are expected to provide sufficient preliminary data for subsequent investigator-initiated research that is relevant to the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. The NIH and the FDA have formed an interagency partnership to foster research relevant to tobacco regulatory science within the framework of the FSPTCA.
Categories: NIH-Funding

Tobacco Regulatory Science (R01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 11/20/2017 - 02:52
Funding Opportunity RFA-OD-18-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Categories: NIH-Funding

Tobacco Regulatory Science (R21 Clinical Trial Optional)

NIH Funding Announcements - Mon, 11/20/2017 - 02:52
Funding Opportunity RFA-OD-18-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Categories: NIH-Funding

Mentored Research Scientist Development Award (Parent K01 -Independent Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 11/20/2017 - 02:19
Funding Opportunity PA-18-369 from the NIH Guide for Grants and Contracts. The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PA-18-363).
Categories: NIH-Funding